Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

Next Previous
Trial Profile

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FMC-376 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms PROSPER
  • Sponsors Frontier Medicines

Most Recent Events

  • 09 Jan 2025 According to a Frontier Biotechnologies media release, interim clinical data for FMC-376 is expected 2H 2025.
  • 25 Jun 2024 According to a Frontier Biotechnologies media release, the company announced the additional close of $20 million of its Series C financing, with participation from investors including Deep Track Capital and ArrowMark Partners, bringing the total raised to $100 million in this round.The financing proceeds will support further advancement of Frontier's FMC-376 that is currently in the Phase 1/2 PROSPER trial.
  • 04 Jun 2024 Trial design from this study were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top